- In May 2024, Google DeepMind unveiled the third version of its AlphaFold AI model, designed to enhance drug development and improve disease targeting. This advanced version enables researchers at DeepMind and Isomorphic Labs to analyze the behavior of all molecules, including human DNA
- In April 2024, Xaira Therapeutics, an innovative company specializing in AI-powered drug discovery and development, secured over USD 1 Million during a collaborative funding round with ARCH Venture Partners and Foresite Labs. Utilizing machine learning, data generation models, and therapeutic product development, the company focuses on addressing drug targets that have traditionally been difficult to tackle
- In December 2023, MilliporeSigma, the life science division of Merck, launched AIDDISON, a cutting-edge drug discovery software. This platform bridges the gap between virtual molecule design and real-world manufacturability by integrating the Synthia retrosynthesis software API. It combines generative AI, machine learning, and computer-aided drug design to streamline drug development processes
- In May 2023, Google launched two innovative AI-driven tools aimed at aiding biotech and pharmaceutical companies in accelerating drug discovery and refining precision medicine. These solutions are designed to reduce the time and expense involved in introducing new treatments to the U.S. market. Early adopters of these tools include Cerevel Therapeutics, Pfizer, and Colossal Biosciences.
Frequently Asked Questions
The major factors driving the growth of the artificial intelligence (ai) in drug discovery market is rising R&D investments in pharmaceutical industry.
The primary challenges include high initial investment costs.
The oncology segment is currently dominating the artificial intelligence (AI) in drug discovery market.
